Kentaro Ito

1.2k total citations
66 papers, 699 citations indexed

About

Kentaro Ito is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Kentaro Ito has authored 66 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Kentaro Ito's work include Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (24 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Kentaro Ito is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (24 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Kentaro Ito collaborates with scholars based in Japan, United States and Singapore. Kentaro Ito's co-authors include Osamu Hataji, Osamu Taguchi, Yuta Adachi, Rui Yamaguchi, Ryo Kimura, Hiromichi Ebi, Tuan Zea Tan, Yuko Hayashi, Esteban C. Gabazza and Yoichi Nishii and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Kentaro Ito

59 papers receiving 684 citations

Peers

Kentaro Ito
Ryo Ko Japan
Lingzhi Hong United States
Luis Manuel Martínez-Barrera Mexico
Ichiro Nakachi Japan
Sung Jin Yoon South Korea
Giuseppe Colantuoni Italy
Pierre‐Jean Souquet France
Qiong Zhao China
Muhammad Alamgeer Australia
Elisa Tassinari Italy
Ryo Ko Japan
Kentaro Ito
Citations per year, relative to Kentaro Ito Kentaro Ito (= 1×) peers Ryo Ko

Countries citing papers authored by Kentaro Ito

Since Specialization
Citations

This map shows the geographic impact of Kentaro Ito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kentaro Ito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kentaro Ito more than expected).

Fields of papers citing papers by Kentaro Ito

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kentaro Ito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kentaro Ito. The network helps show where Kentaro Ito may publish in the future.

Co-authorship network of co-authors of Kentaro Ito

This figure shows the co-authorship network connecting the top 25 collaborators of Kentaro Ito. A scholar is included among the top collaborators of Kentaro Ito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kentaro Ito. Kentaro Ito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ikeda, Satoshi, Takashi Ogura, Terufumi Kato, et al.. (2024). Nintedanib Plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society. 21(4). 635–643. 6 indexed citations
2.
Nishii, Yoichi, Tadashi Sakaguchi, Yuki Nakamura, et al.. (2023). Close-to-lesion transbronchial biopsy: a novel technique to improve suitability of specimens for genetic testing in patients with peripheral pulmonary lesions. Scientific Reports. 13(1). 14724–14724. 3 indexed citations
3.
4.
Ito, Atsushi, Yūta Suzuki, Tadashi Sakaguchi, et al.. (2023). Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma. Anticancer Research. 43(11). 5197–5204. 1 indexed citations
5.
Ikeda, Satoshi, Takashi Ogura, Takaaki Tokito, et al.. (2023). MA18.08 A Phase 2 Study of Carboplatin, Etoposide and Nintedanib for Unresectable Small-Cell Lung Cancer with Idiopathic Pulmonary Fibrosis. Journal of Thoracic Oncology. 18(11). S168–S168. 1 indexed citations
6.
7.
Morimoto, Kenji, Ryo Sawada, Tadaaki Yamada, et al.. (2022). A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. JTO Clinical and Research Reports. 3(9). 100388–100388. 5 indexed citations
8.
Shiraishi, Yoshimasa, Takayuki Shimose, Hidenobu Ishii, et al.. (2022). Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases. Cancer Management and Research. Volume 14. 3449–3453. 3 indexed citations
9.
Ito, Kentaro, Masahiro Morise, Kazushige Wakuda, et al.. (2021). A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. ESMO Open. 6(3). 100115–100115. 33 indexed citations
10.
Miyawaki, Taichi, Hirotsugu Kenmotsu, Hideyuki Harada, et al.. (2021). Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer. 21(1). 1121–1121. 5 indexed citations
11.
Sakaguchi, Tadashi, Yasumasa Kokubo, Kazuki Furuhashi, et al.. (2021). An Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor. Clinical Lung Cancer. 23(3). e273–e275. 8 indexed citations
12.
Ito, Kentaro, Shinya Sakata, Kohei Otsubo, et al.. (2021). MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L. Annals of Oncology. 32. S297–S297. 1 indexed citations
13.
Adachi, Yuta, Kentaro Ito, Yuko Hayashi, et al.. (2020). Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(22). 5962–5973. 146 indexed citations
14.
Chen, Hao, Nobuyuki Horita, Kentaro Ito, et al.. (2020). Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis. Therapeutic Advances in Medical Oncology. 12. 3863580881–3863580881. 7 indexed citations
15.
Sakaguchi, Tadashi, Kentaro Ito, Kazuki Furuhashi, et al.. (2019). Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria. Respiratory Investigation. 57(5). 466–471. 36 indexed citations
16.
Watanabe, Satomi, Takeharu Yamanaka, Kentaro Ito, et al.. (2019). OA02.06 The Sequential Therapy of Crizotinib Followed by Alectinib: Real World Data of 840 Patients with NSCLC Harboring ALK-Rearrangement (WJOG9516L). Journal of Thoracic Oncology. 14(10). S209–S210. 1 indexed citations
17.
Nishii, Yoichi, Taro Yasuma, Kentaro Ito, et al.. (2019). Factors leading to failure to diagnose pulmonary malignant tumors using endobronchial ultrasound with guide sheath within the target lesion. Respiratory Research. 20(1). 207–207. 14 indexed citations
18.
Nakamura, Yuki, Tetsu Kobayashi, Yoichi Nishii, et al.. (2018). Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer. Thoracic Cancer. 9(11). 1476–1482. 7 indexed citations
19.
Horita, Nobuyuki, Kentaro Nakashima, Yuji Shibata, et al.. (2017). The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis. Scientific Reports. 7(1). 13185–13185. 15 indexed citations
20.
Ito, Kentaro, Koji Katsuta, Tetsu Kobayashi, et al.. (2016). “Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy. Journal of Thoracic Oncology. 11(10). e117–e119. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryo Ko Breakdown of academic impact, for papers by Lingzhi Hong Breakdown of academic impact, for papers by Luis Manuel Martínez-Barrera Breakdown of academic impact, for papers by Ichiro Nakachi Breakdown of academic impact, for papers by Sung Jin Yoon Breakdown of academic impact, for papers by Giuseppe Colantuoni Breakdown of academic impact, for papers by Pierre‐Jean Souquet Breakdown of academic impact, for papers by Qiong Zhao Breakdown of academic impact, for papers by Muhammad Alamgeer Breakdown of academic impact, for papers by Elisa Tassinari
Rankless by CCL
2026